Product Description: Tavolixizumab (MEDI 0562; Tavolimab) is a human monoclonal antibody to TNFRSF4 (TNF receptor superfamily member 4) for use in cancer immunology research[1].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]Claudia Giampietri, et al. Analysis of gene expression levels and their impact on survival in 31 cancer-types patients identifies novel prognostic markers and suggests unexplored immunotherapy treatment options in a wide range of malignancies. J Transl Med. 2022 Oct 12;20(1):467.